Ernexa Therapeutics (ERNAW) Depreciation and Depletion (2018 - 2021)

Ernexa Therapeutics has reported Depreciation and Depletion for 3 years, with the latest figure at $25163.0 in Q1 2021.

• For the quarter ending Q1 2021, Depreciation and Depletion rose 9.41% year-over-year to $25163.0; the trailing twelve-month figure through Mar 2021 stood at $76162.0 (changed N/A YoY), and the FY2025 full-year result was $100000.0, changed 0.0% from the prior year.
• Depreciation and Depletion for Q1 2021 stood at $25163.0, up from $22999.0 in the prior quarter.
• The five-year high for Depreciation and Depletion was $25163.0 in Q1 2021, with the low at $7000.0 in Q1 2018.
• Historically, Depreciation and Depletion has averaged $19040.5 across 3 years, with a median of $21999.5 in 2018.
• The largest YoY upside for Depreciation and Depletion was 9.41% in 2021 against a maximum downside of 9.41% in 2021.
• Ernexa Therapeutics' Depreciation and Depletion stood at $21000.0 in 2018, then grew by 9.52% to $22999.0 in 2020, then increased by 9.41% to $25163.0 in 2021.
• The last three Depreciation and Depletion figures came in at $25163.0 (Q1 2021), $22999.0 (Q1 2020), and $21000.0 (Q2 2018), per Business Quant data.